Doses - CISPLATIN
For more information, refer to the protocol references found in the appendix or otherprotocols found in small animal internal medicine references. Additionally, it is strongly recommend to consult the following reference if cisplatin therapy is being considered: Shapiro, W. 1989.
Cisplatin Chemotherapy. In Current Veterinary Therapy X: Small Animal Practice. Edited by R. W.
Kirk. 497-502. Philadelphia: W.B. Saunders.
Warning: Dogs must undergo saline diuresis before and after cisplatin therapy to reduce the potential for nephrotoxicity development. Some clinicians also recommend using either mannitol andfurosemide with saline, but this is somewhat controversial.Dogs:
For potentially susceptible carcinomas and sarcomas:
a) 60 mg/m2 IV over 20 minutes every 3 weeks. Intravenous normal saline is given at 20ml/kg/hr for 4 hours before and for 2 hours after cisplatin administration. If animalvomits, give chlorpromazine at 0.5 mg/kg IV or SQ; repeat prn to control vomiting.(Knapp et al. 1988)
b) 30 - 50 mg/m2 every 3 weeks. Pretreat with fluids at 60 ml/kg for 12 hours beforedosing. Give mannitol 0.5 mg/kg 30 minutes before cisplatin. Give cisplatin as a slowdrip over 1-6 hours and fol ow with another 12 hours of fluids at 60 ml/kg. (Macy1986)
c) 60 - 70 mg/m2 IV drip q3-5 weeks. Perform saline diuresis before and after treatment.(MacEwen and Rosenthal 1989)
Monitoring Parameters - Adapted primarily from the reference by Shapiro (Shapiro 1989).
1) Toxicity. Baseline laboratory data: urinalysis, hemogram, platelet count, serum biochemical and electrolyte determination. Repeat tests before each dose if animal is receivinghigh-dose therapy (»monthly) or prn if signs/symptoms of toxicity develop. Animalsreceiving frequent small doses should be monitored at least weekly. Not recommended touse cisplatin if WBC is <3200/µl, platelets <100, 000, creatinine clearance is <1.4ml/min/kg, or uremia, electrolyte or acid-base imbalance is present. Reduce dose if rapiddecreases occur with either WBC or platelets, changes in urine specific gravity or serumelectrolytes, elevated serum creatinine or BUN, or if creatinine clearance is >1.4 but <2.9ml/min/kg.
2) Efficacy. Tumor measurement and radiography at least monthly. In one study (Knapp etal. 1988), the authors state that dogs should be evaluated at 42 days into therapy. Dogsdemonstrating complete or partial remission or stable disease should receive additionaltherapy. Dogs whose disease has progressed should have cisplatin therapy stopped andreceive alternate therapies if warranted.
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related mortality.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
Platinol-AQ® (Bristol-Myers Oncology); (Rx)
Cisplatin Chemotherapy. In Current Veterinary Therapy X: Small Animal Practice. Edited by R. W.
Kirk. 497-502. Philadelphia: W.B. Saunders.
Warning: Dogs must undergo saline diuresis before and after cisplatin therapy to reduce the potential for nephrotoxicity development. Some clinicians also recommend using either mannitol andfurosemide with saline, but this is somewhat controversial.
Dogs: 
For potentially susceptible carcinomas and sarcomas: a) 60 mg/m2 IV over 20 minutes every 3 weeks. Intravenous normal saline is given at 20ml/kg/hr for 4 hours before and for 2 hours after cisplatin administration. If animalvomits, give chlorpromazine at 0.5 mg/kg IV or SQ; repeat prn to control vomiting.(Knapp et al. 1988)
b) 30 - 50 mg/m2 every 3 weeks. Pretreat with fluids at 60 ml/kg for 12 hours beforedosing. Give mannitol 0.5 mg/kg 30 minutes before cisplatin. Give cisplatin as a slowdrip over 1-6 hours and fol ow with another 12 hours of fluids at 60 ml/kg. (Macy1986)
c) 60 - 70 mg/m2 IV drip q3-5 weeks. Perform saline diuresis before and after treatment.(MacEwen and Rosenthal 1989)
Monitoring Parameters - Adapted primarily from the reference by Shapiro (Shapiro 1989).
1) Toxicity. Baseline laboratory data: urinalysis, hemogram, platelet count, serum biochemical and electrolyte determination. Repeat tests before each dose if animal is receivinghigh-dose therapy (»monthly) or prn if signs/symptoms of toxicity develop. Animalsreceiving frequent small doses should be monitored at least weekly. Not recommended touse cisplatin if WBC is <3200/µl, platelets <100, 000, creatinine clearance is <1.4ml/min/kg, or uremia, electrolyte or acid-base imbalance is present. Reduce dose if rapiddecreases occur with either WBC or platelets, changes in urine specific gravity or serumelectrolytes, elevated serum creatinine or BUN, or if creatinine clearance is >1.4 but <2.9ml/min/kg.
2) Efficacy. Tumor measurement and radiography at least monthly. In one study (Knapp etal. 1988), the authors state that dogs should be evaluated at 42 days into therapy. Dogsdemonstrating complete or partial remission or stable disease should receive additionaltherapy. Dogs whose disease has progressed should have cisplatin therapy stopped andreceive alternate therapies if warranted.
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related mortality.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
Human-Approved Products:
Cisplatin Injection 1 mg/ml in 50 and 100 ml vialsPlatinol-AQ® (Bristol-Myers Oncology); (Rx)